ストックスクリーナーアプリを入手
33.82
2.28%
-0.79
前日終値:
$34.61
開ける：
$34.61
24時間の取引高:
1.58M
Relative Volume:
0.74
時価総額：
$3.33B
収益：
$669.43M
当期純損益:
$-609.36M
株価収益率:
-5.5387
EPS:
-6.1061
ネットキャッシュフロー:
$-507.20M
1週間 パフォーマンス:
+1.05%
1か月 パフォーマンス:
+47.24%
6か月 パフォーマンス:
+50.24%
1年 パフォーマンス:
+8.97%
1日の値動き範囲:
$32.72
$34.81
1週間の範囲:
$32.72
$36.57
52週間の値動き範囲:
$18.29
$39.89
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
Compare RARE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
33.82 | 3.33B | 669.43M | -609.36M | -507.20M | -6.1061 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-24 | ダウングレード | Goldman | Buy → Neutral |
| 2025-10-20 | 開始されました | Wells Fargo | Overweight |
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
Ultragenyx Pharmaceutical (RARE) Is Up 7.4% After Index Migration To Russell 2000 And Value BenchmarksHas The Bull Case Changed? - Sahm
(RARE) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Ultragenyx releases 2025 impact report on rare disease work - Investing.com
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - The Manila Times
Ultragenyx Releases 2025 Impact Report Highlighting Progress in Rare Disease Therapies, Patient Access and Sustainability - Quiver Quantitative
Ultragenyx releases 2025 impact report on rare disease work By Investing.com - Investing.com Canada
Ultragenyx Releases 2025 Impact Report Emphasizing - GlobeNewswire
Ultragenyx says five rare-disease programs reached pivotal trials in 2025 - Stock Titan
RBC Capital Adjusts Ultragenyx Pharmaceutical Price Target to $40 From $35, Maintains Outperform Rating - Moomoo
RBC Capital Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Raises Target Price to $40 - Moomoo
Ultragenyx CFO Howard Horn sells $155,644 in company shares By Investing.com - Investing.com South Africa
Form 4 Ultragenyx For: 6 July By Investing.com - Investing.com South Africa
Ultragenyx CFO Howard Horn sells $155,644 in company shares - Investing.com
Ultragenyx (RARE) CFO sells 4,698 shares, retains 100,991 stake - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Ultragenyx Pharmaceutical Inc.'s (NASDAQ:RARE) Shift From Loss To Profit - 富途牛牛
RAREUltragenyx Pharmaceutical Inc Latest SEC Filings - Finviz
Form 144 ULTRAGENYX PHARMACEUTICAL INC. For: 1 July By Investing.com - Investing.com Canada
RARE (NASDAQ: RARE) affiliate reports insider sales and scheduled awards - Stock Titan
RARE Stock Edges Up On Priority Review For Gene Therapy In Rare Metabolic Disorder - Stocktwits
Does Ultragenyx (RARE) Shifting Into Small‑Cap Value Indices Recast Its Rare‑Disease Growth Story? - simplywall.st
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell Midcap Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Value Benchmark - marketscreener.com
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 2000 Growth Benchmark - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Growth Benchmark - marketscreener.com
Price to book forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) dropped from Russell 1000 Dynamic Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell Midcap Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) dropped from Russell 1000 Index - marketscreener.com
Ultragenyx Pharmaceutical Inc.(NasdaqGS: RARE) added to Russell 2000 Dynamic Index - marketscreener.com
RARE Stock Slumps On Multiple Wall Street Price Target Slashes, Clinical Pipeline Uncertainty - Stocktwits
Enterprise value to revenue forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Enterprise value to EBIT forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical Inc.(NasdaqGS:RARE) added to Russell 3000E Value Benchmark - marketscreener.com
Price to sales forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Price to earnings forward of Ultragenyx Pharmaceutical Inc. – NASDAQ:RARE - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (NASDAQ:RARE) - TradingView
Ultragenyx Pharmaceutical, Inc. Actuals & Estimates (BX:UP0) - TradingView
RARE Forecast — Price Target — Prediction for 2027 - TradingView
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity - Seeking Alpha
Ultragenyx Pharmaceutical Inc. $RARE Shares Bought by Caitong International Asset Management Co. Ltd - MarketBeat
Ultragenyx grants 44,409 restricted stock units to 15 new non-executive officers as an inducement. - Pluang
Ultragenyx awards 44,409 RSUs to 15 new hires - Stock Titan
Ultragenyx Pharmaceutical Inc (RARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ultragenyx Pharmaceutical Inc - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):